Abstract
The data in this paper indicate that the combined treatment of pancreatic ductal adenocarcinoma in mice with gemcitabine and an antibody that targets connective tissue growth factor has greater efficacy than either treatment alone owing to a reduction in the expression levels of XIAP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
